文献速递血液净化与透析

起始增量血液透析与标准血液透析及腹膜透析患者的结局比较

Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

单中心回顾性分析313例2013年1月至2020年12月起始透析的成人,其中234例起始血液透析(166例标准每周三次血透、68例增量血透)、79例腹膜透析。增量血透较标准血透生存改善(HR 0.49,95%CI 0.26-0.93,P=0.029),腹膜透析生存相似;起始模式与1年住院天数无显著相关。

要点

  • 增量血透较标准血透生存改善(HR 0.49,95%CI 0.26-0.93,P=0.029)。
  • 腹膜透析与标准血透生存相似,起始模式与1年住院天数无显著相关。
  • 68例增量血透中45例平均9.8±9.1个月后转为标准血透,持续增量者糖尿病更少(P=0.007)。

核心结论

  • 增量血透适用于 selected 起始透析患者,可在转为标准血透前维持相当时间,糖尿病为风险因素。
  • 起始增量血透较标准血透或腹膜透析与生存改善相关,但1年住院天数相似。
  • 作者认为需等待随机对照试验结果后再大规模实施增量血透方案。

研究设计与样本

  • 单大学中心前瞻性 assembled 队列的回顾性分析,纳入2013年1月至2020年12月所有起始透析的成人。
  • 共313例,234例起始血透(166例标准每周三次血透、68例增量血透),79例腹膜透析。

主要发现

  • 平均随访33.1±30.8个月,124例(39.6%)死亡。
  • 增量血透较标准血透生存改善(HR 0.49,95%CI 0.26-0.93,P=0.029),腹膜透析与标准血透生存相似。
  • 起始肾脏替代治疗模式与1年住院天数无显著相关。
  • 研究结束时10例仍在增量血透,45例平均9.8±9.1个月后转为标准血透;持续增量血透者糖尿病更少(P=0.007)。

临床怎么用

  • 作者认为增量血透适用于 selected 起始透析患者,可在转为标准血透前维持相当时间,糖尿病为风险因素。
  • 作者认为需等待随机对照试验结果后再大规模实施增量血透方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Residual kidney function is considered better preserved with incremental haemodialysis (I-HD) or peritoneal dialysis (PD) as compared with conventional thrice-weekly HD (TW-HD) and is associated with improved survival. We aimed to describe outcomes of patients initiating dialysis with I-HD, TW-HD or PD. METHODS: We conducted a retrospective analysis of a prospectively assembled cohort in a single university centre including all adults initiating dialysis from January 2013 to December 2020. Primary and secondary endpoints were overall survival and hospitalization days at 1 year, respectively. RESULTS: We included 313 patients with 234 starting on HD (166 TW-HD and 68 I-HD) and 79 on PD. At the end of the study, 10 were still on I-HD while 45 transitioned to TW-HD after a mean duration of 9.8 ± 9.1 months. Patients who stayed on I-HD were less frequently diabetics (P = .007). Mean follow-up was 33.1 ± 30.8 months during which 124 (39.6%) patients died. Compared with patients on TW-HD, those on I-HD had improved survival (hazard ratio 0.49, 95% confidence interval 0.26-0.93, P = .029), while those on PD had similar survival. Initial kidney replacement therapy modality was not significantly associated with hospitalization days at 1 year. CONCLUSIONS: I-HD is suitable for selected patients starting dialysis and can be maintained for a significant amount of time before transition to TW-HD, with diabetes being a risk factor. Although hospitalization days at 1 year are similar, initiation with I-HD is associated with improved survival as compared with TW-HD or PD. Results of randomized controlled trials are awaited prior to large-scale implementation of I-HD programmes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Jaques DA, Ponte B, Haidar F, et al. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2022. PMID: 35731591. doi:10.1093/ndt/gfac205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。